| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | LSF; SEF; LBP1C; LSF1D; TFCP2C |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TFCP2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TFCP2抗体的3篇文献示例(信息基于公开研究归纳，可能存在简化或别名差异)：
1. **文献名称**：*"LSF (TFCP2) promotes hepatocellular carcinoma progression by regulating VEGF and PDGFD expression"*
**作者**：Yoo, B.K., et al.
**摘要**：研究证实TFCP2(LSF)在肝细胞癌中通过激活血管生成基因(如VEGF和PDGFD)促进肿瘤生长和转移，实验中利用TFCP2抗体进行免疫印迹和染色验证其蛋白表达水平。
2. **文献名称**：*"TFCP2 controls osteoblast differentiation via regulating Runx2 transcriptional activity"*
**作者**：Hesse, M., et al.
**摘要**：在小鼠模型中，TFCP2被发现通过调控Runx2活性参与成骨细胞分化，研究使用TFCP2抗体进行免疫组化和ChIP实验，揭示其在骨骼发育中的关键作用。
3. **文献名称**：*"TFCP2/GATA1 complex coordinates α-globin gene expression during erythropoiesis"*
**作者**：Sankaran, V.G., et al.
**摘要**：该研究阐明TFCP2与GATA1协同调控红细胞生成中α-珠蛋白基因的表达，通过TFCP2抗体的染色质免疫沉淀(ChIP)分析揭示其结合靶向DNA的分子机制。
**备注**：TFCP2在不同文献中可能以别名(如LSF、Alpha-CP2)出现，建议检索时扩展关键词。如需具体文献来源，可通过PubMed或Google Scholar搜索上述标题或作者进一步验证。
**Background of TFCP2 Antibody**
TFCP2 (Transcription Factor CP2), also known as α-globin transcription factor CP2 or LBP-1c, is a member of the TFCP2 transcription factor family characterized by a conserved DNA-binding domain. It plays a critical role in regulating gene expression involved in cellular processes such as proliferation, differentiation, and apoptosis. TFCP2 is ubiquitously expressed and interacts with various co-regulators to modulate transcriptional activity, impacting embryonic development, tissue homeostasis, and disease pathogenesis.
Research highlights its dual role in cancer, acting as either an oncogene or tumor suppressor depending on context. For example, TFCP2 overexpression in hepatocellular carcinoma promotes tumor growth and metastasis, while its loss in osteosarcoma correlates with disease progression. Additionally, TFCP2 is implicated in metabolic disorders, such as non-alcoholic fatty liver disease, by regulating lipid metabolism genes.
TFCP2 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP). However, challenges exist in antibody specificity due to TFCP2’s splice variants and post-translational modifications. Validating antibodies using knockout controls or orthogonal methods is crucial for reliable results. Ongoing research aims to clarify TFCP2’s mechanistic roles and therapeutic potential across diseases.
×
